The National Institute for Health and Clinical Excellence (NICE) has been invited to carry out an appraisal of atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer.
We have recently invited stakeholders to respond to a written consultation on the draft scope which closed on 06 February 2019.
The company developing atezolizumab has advised NICE that they do not intend to participate in a Technology Appraisal for this topic. In light of this information NICE will not be progressing with the scoping exercise.
If you have any comments or concerns please contact the Project Manager for this appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk)